Antibiotics

In a world where multi–drug resistant (MDR) bacterial infections are increasingly common, it is imperative that we scrutinize the use of antimicrobial drugs (AMDs) and limit them to situations in which they are truly necessary. According to the CDC’s 2019 Antibiotic Resistance Threats Report, there are 2.8 million MDR infections and 35,000 associated deaths annually in the United States.¹ Even more concerning, the WHO estimates approximately 700,000 global deaths each year due to MDR infections—a number projected to reach 10 million annually if practices do not change.² Overuse and misuse of AMDs in both humans and animals contribute significantly to the development of antimicrobial resistant (AMR) bacterial populations. Many pathogens considered major threats to human health by the CDC have zoonotic potential, and the shared use of similar antimicrobial classes in human and veterinary medicine facilitates transmission of resistance between species.

Periodontal disease results from a shift in the oral microflora due to biofilm and plaque accumulation under the gumline, as well as the host’s inflammatory response to that shift. Inflammatory cells and osteoclasts contribute to tissue destruction, leading to periodontal pockets, bone loss, and oral pain. Antibiotics may temporarily reduce clinical signs, but they do not penetrate the protective biofilm in which periodontal pathogens reside, and thus offer only transient relief. They also disrupt the normal symbiotic oral and gastrointestinal microbiota. For these reasons, antibiotics are never a definitive treatment for periodontal disease; instead, a comprehensive oral health assessment and treatment (COHAT) under anesthesia is required. Except in severe oral inflammatory conditions such as osteomyelitis with an open fistula, pre-COHAT treatments should focus on anti-inflammatory and pain-control strategies rather than antibiotics. Even when antibiotics help reduce active infection, they must always be followed by a COHAT, as antibiotics alone cannot resolve the disease. Likewise, endodontic infections causing facial swelling or draining tracts cannot resolve without extraction or root canal therapy.

Concerns about peri-operative bacteremia and postoperative complications—such as extraction-site infection, dehiscence, systemic infection, or endocarditis—often drive the use of peri- or postoperative antibiotics in veterinary dentistry. Although a transient bacteremia occurs during dental scaling, research shows it resolves within one hour,³ and human studies demonstrate it is no more significant than the bacteremia associated with routine tooth brushing, flossing, or chewing.⁴⁶ In a 2021 study, prophylactic antibiotics did not reduce postoperative infection rates in dogs undergoing major oromaxillofacial surgery; instead, anesthesia time was the only significant risk factor.⁷ Limited evidence exists for humans with maxillofacial trauma, but the general consensus is that antibiotics are unnecessary for conservatively treated fractures and should not be continued beyond 24 hours for open fracture repair; longer durations may even increase infection risk.⁸ Postoperative infections in routine dentistry procedures are rare,⁹ pet owners should be counseled that infection is uncommon but possible and educated on signs to monitor.

Historically, prophylactic antibiotics were recommended for patients with orthopedic implants, heart disease, or immunocompromised conditions such as diabetes, autoimmune disorders, HIV/FIV, or those undergoing chemotherapy. However, recent studies show no evidence supporting the use of prophylactic antibiotics in patients with orthopedic implants⁶ or in most forms of heart disease.¹⁰¹² In 2017, the American Dental Association and American Academy of Orthopedic Surgeons jointly stated that prophylactic antibiotics are rarely indicated for patients with orthopedic implants.¹³ A small subset of high-risk cardiac patients—such as those with prosthetic heart valves, repaired or unrepaired cyanotic congenital heart disease, ventricular assist devices, past infective endocarditis, or cardiac transplant recipients—may require a single oral antibiotic dose 30–60 minutes before invasive dental procedures, which significantly reduces infective endocarditis risk.¹⁴,¹⁵ These conditions are extremely rare in animals. Given the risks of antimicrobial resistance and disruption of normal microflora, prophylactic antibiotics generally pose greater risk than benefit in most patients.

Limited data exist for immunocompromised or diabetic veterinary patients. Current recommendations restrict prophylactic antibiotic use to patients with severely uncontrolled diabetes,¹⁶ severe primary immunodeficiency, severe neutropenia, or those receiving high-dose immunosuppressive therapy.¹⁷ Invasive dental surgery should be avoided in chemotherapy and stem cell transplant patients and all dental disease should be addressed prior to starting treatment whenever possible18. In human medicine, dental disease is systematically addressed before orthopedic surgery or chemotherapy initiation—a practice that could be better implemented in veterinary medicine given that 85% of pets over age three have some degree of dental disease.

Because specific veterinary guidelines are limited, decisions regarding antibiotic use can be challenging, and client concerns often lead to unnecessary prescriptions. The current American Veterinary Dental College (AVDC) position statement recommends systemic antibiotics to reduce bacteremia in animals that are immunocompromised, have certain systemic diseases (e.g., subaortic stenosis or severe hepatic/renal disease), or have severe oral infections.¹⁹ However, this statement is broad and does not fully reflect current research or human dental recommendations. Fortunately, the AVMA, AAHA, and AAFP have recently released antimicrobial stewardship resources to guide clinicians. The 2022 AAFP/AAHA Antimicrobial Stewardship Guidelines clearly state that systemic antimicrobials are not indicated for routine dental prophylaxis or after tooth extraction; they are not a substitute for surgical management of periodontitis; and most periapical abscesses resolve with debridement alone.²⁰ Additional studies are emerging that evaluate antimicrobial use in veterinary dentistry and propose evidence-based changes.²¹,²²

Human medicine literature suggests that antibiotics are frequently prescribed because clinicians believe patients expect them,²³ and this phenomenon occurs frequently in veterinary medicine as well. Education is essential: clinicians must explain risks, benefits, and alternatives and make treatment decisions based on science. Responsible antimicrobial stewardship is also a public-health obligation.

When antibiotic therapy is indicated, choosing an appropriate drug regimen is essential. Bacteroides, a common anaerobe and pathogen in periodontal disease, shows significant resistance to clindamycin and occasionally to amoxicillin–clavulanate; metronidazole is generally more effective.²⁴,²⁵ Porphyromonas spp., another common periodontal pathogen in dogs, shows resistance to clindamycin.²⁶ Clindamycin also does not cover Enterococcus or gram-negative aerobes. Amoxicillin–clavulanate provides broad coverage of gram-positive and gram-negative aerobes as well as anaerobes. In high-risk patients requiring infective-endocarditis prophylaxis (rare), a single IV dose of ampicillin (with or without sulbactam) 30–60 minutes before dental surgery is typically sufficient. For active infection, culture and susceptibility testing is ideal to tailor therapy, while recognizing that commensal oral organisms will also be present.

Some oral diseases more complex than periodontal or endodontic disease may require antibiotics. In feline chronic gingivostomatitis (FCGS) and canine chronic ulcerative stomatitis (CCUS), peri- and postoperative antibiotics may be indicated when healthy gingival closure is compromised, disease is extensive, secondary infection is evident (purulent discharge or crusts), or the patient is immunocompromised. However, recent research shows increased AMR in FCGS cats, particularly to amoxicillin–clavulanate, and suggests fungal overgrowth may contribute to disease.²⁷ Therefore, postoperative antibiotics should ideally be limited to 3–5 days to reduce selective pressure. Because FCGS and CCUS are immune-mediated diseases, pain control and immunomodulatory therapy are the mainstay of treatment.²⁸ Pentoxifylline, niacinamide, and doxycycline or metronidazole have recently been described as a treatment regimen for CCUS.²⁹ Additionally, hyaluronic acid (Periovive) is showing promising results in treatment of stomatitis as well as reducing healing times and post operative infections.30,31 More research is needed to identify additional effective therapies for these painful conditions.

Other severe oral diseases, including osteomyelitis and osteonecrosis of the jaw, may warrant longer antibiotic courses. Emerging data show promising outcomes using pentoxifylline and vitamin E following surgery for osteonecrosis.32-34 Osteonecrosis with an open draining fistula, often due to endodontic infection from fractured teeth, may require antibiotics and NSAIDs until surgery can be performed. Some cases may benefit from sedation to lance and flush abscesses to minimize antibiotic needs. For severe osteomyelitis that cannot be fully debrided surgically, 14 days of amoxicillin–clavulanate and/or metronidazole may be necessary and, in rare cases, extended to 6–8 weeks depending on clinical response and repeat imaging. Minimal veterinary research exists regarding antibiotic use for open jaw fractures, but human literature recommends limiting therapy to 24 hours.⁸ Veterinary recommendations often range from 3–7 days. For major maxillofacial surgery, including tumor resection, perioperative antibiotics generally do not reduce postoperative infection rates but may be considered for procedures exceeding six hours.⁷ For most other dental conditions—particularly those without fever—anti-inflammatory medications can adequately control pain and swelling until definitive surgical treatment is performed.

Ultimately, while antibiotics are valuable tools for managing bacterial disease, they must be used judiciously and only when indicated. Periodontal disease is best treated through mechanical removal of plaque and calculus, root planing, endodontic therapy, and/or extraction, allowing the body to resolve remaining inflammation and infection. Prophylactic antibiotic use should be reserved for truly high-risk patients, who are uncommon in veterinary medicine. At Mainely Veterinary Dentistry, we take antimicrobial stewardship seriously; please speak with your technician if you have questions about antibiotic use in your pet.

 

We’ve put this information into an easy-to-share brochure.

If you’d like some for your clinic or clients, email us anytime at info@mainelyvetdentistry.com

 

 


References

  1. Centers for Disease Control and Prevention. (2023). CDC’s 2019 Antibiotic Resistance Threats Report.
  2. World Health Organization, B. (2019). No time to wait: securing the future from drug-resistant infections. World Health Organization: Geneva, Switzerland.
  3. Blazevich M, Miles C. The Presence of Bacteremia in 13 Dogs Undergoing Oral Surgery Without the Use of Antibiotic Therapy. Journal of Veterinary Dentistry. 2023;41(4):312-323. doi:10.1177/08987564231207208
  4. Sconyers, J. R., Crawford, J. J., & Moriarty, J. D. (1973). Relationship of bacteremia to toothbrushing in patients with periodontitis. The Journal of the American Dental Association87(3), 616-622.
  5. Forner, L., Larsen, T., Kilian, M. and Holmstrup, P. (2006), Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. Journal of Clinical Periodontology, 33: 401-407. https://doi.org/10.1111/j.1600-051X.2006.00924.x
  6. Watters, William III, MD; Rethman, Michael P. DDS, MS; Hanson, Nicholas Buck MPH; Abt, Elliot DDS; Anderson, Paul A. MD; Carroll, Karen C. MD, FCAP; Futrell, Harry C. DMD; Garvin, Kevin MD; Glenn, Stephen O. DDS; Hellstein, John DDS, MS; Hewlett, Angela MD, MS; Kolessar, David MD; Moucha, Calin MD; O’Donnell, Richard J. MD; O’Toole, John E. MD; Osmon, Douglas R. MD; Evans, Richard Parker MD; Rinella, Anthony MD; Steinberg, Mark J. DDS, MD; Goldberg, Michael MD; Ristic, Helen PhD; Boyer, Kevin; Sluka, Patrick MPH; Martin, William Robert III, MD; Cummins, Deborah S. PhD; Song, Sharon PhD; Woznica, Anne MLIS; Gross, Leeaht MPH. Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures. Journal of the American Academy of Orthopaedic Surgeons 21(3):p 180-189, March 2013. | DOI: 10.5435/JAAOS-21-03-180
  7. Rigby BE, Malott K, Hetzel SJ and Soukup JW (2021) Incidence and Risk Factors for Surgical Site Infections Following Oromaxillofacial Oncologic Surgery in Dogs. Front. Vet. Sci. 8:760628. doi: 10.3389/fvets.2021.760628
  8. Goormans F, Coropciuc R, Vercruysse M, Spriet I, Willaert R, Politis C. Systemic Antibiotic Prophylaxis in Maxillofacial Trauma: A Scoping Review and Critical Appraisal. Antibiotics (Basel). 2022 Apr 5;11(4):483. doi: 10.3390/antibiotics11040483. PMID: 35453234; PMCID: PMC9027173.
  9. Najla Saeed Dar-Odeh, Osama Abdalla Abu-Hammad, Mahmoud Khaled Al-Omiri, Ameen Sameh Khraisat & Asem Ata Shehabi (2010) Antibiotic prescribing practices by dentists: a review, Therapeutics and Clinical Risk Management, , 301-306, DOI: 10.2147/ TCRM.s9736
  10. Wilson, W., Taubert, K. A., Gewitz, M., Lockhart, P. B., Baddour, L. M., Levison, M., … & Durack, D. T. (2007). Prevention of infective endocarditis: guidelines from the American heart association: a guideline from the American heart association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation116(15), 1736-1754.
  11. Thornhill M, Prendergast B, Dayer M, Frisby A, Lockhart P, Baddour LM. Prevention of infective endocarditis in at-risk patients: how should dentists proceed in 2024? Br Dent J. 2024 May;236(9):709-716. doi: 10.1038/s41415-024-7355-2. Epub 2024 May 10. PMID: 38730168; PMCID: PMC11087238.
  12. Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS, Couper DJ, Beaton A, Kilmartin C, Miro JM, Sable C, Jackson MA, Baddour LM; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. Circulation. 2021 May 18;143(20):e963-e978. doi: 10.1161/CIR.0000000000000969. Epub 2021 Apr 15. Erratum in: Circulation. 2021 Aug 31;144(9):e192. doi: 10.1161/CIR.0000000000001012. Erratum in: Circulation. 2022 Apr 26;145(17):e868. doi: 10.1161/CIR.0000000000001066. PMID: 33853363.
  13. Quinn, Robert H. MD; Murray, Jayson N. MA; Pezold, Ryan MA; Sevarino, Kaitlyn S. MBA. Management of Patients with Orthopaedic Implants Undergoing Dental Procedures. Journal of the American Academy of Orthopaedic Surgeons 25(7):p e138-e141, July 2017. | DOI: 10.5435/JAAOS-D-17-00006
  14. Ibrahim AM, Siddique MS. Subacute Bacterial Endocarditis Prophylaxis. [Updated 2024 Feb 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532983/
  15. Sperotto F, France K, Gobbo M, et al. Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2024;9(7):599-610. doi:10.1001/jamacardio.2024.0873
  16. de Leeuw K, Bootsma H, Middel A, Vissink A. AB-profylaxe en immuungecompromitteerde patiënten [Antibiotic prophylaxis and immune-compromised patients]. Ned Tijdschr Tandheelkd. 2019 Oct;126(10):521-525. Dutch. doi: 10.5177/ntvt.2019.10.19065. PMID: 31613281.
  17. Sykara M, Maniatakos P, Tentolouris A, Karoussis IK, Tentolouris N. The necessity of administrating antibiotic prophylaxis to patients with diabetes mellitus prior to oral surgical procedures-a systematic review. Diabetes Metab Syndr. 2022 Oct;16(10):102621. doi: 10.1016/j.dsx.2022.102621. Epub 2022 Sep 24. PMID: 36183455.
  18. Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, Quinn B, Epstein JB, Blijlevens NM, Waltimo T, Passweg JR, Correa ME, Dahllöf G, Garming-Legert KU, Logan RM, Potting CM, Shapira MY, Soga Y, Stringer J, Stokman MA, Vokurka S, Wallhult E, Yarom N, Jensen SB. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36. doi: 10.1007/s00520-014-2378-x. Epub 2014 Sep 5. PMID: 25189149; PMCID: PMC4328129.
  19. The use of antibiotics in veterinary dentistry. American Veterinary Dental College. Revised April 19, 2019. Accessed June 20, 2025. https://avdc.org/about/#pos-stmts
  20. Frey, E., Costin, M., Granick, J., Kornya, M., & Weese, J. S. (2022). 2022 AAFP/AAHA Antimicrobial Stewardship Guidelines. Journal of the American Animal Hospital Association58(4), 1-5. https://doi.org/10.5326/1547-3317-58.4.1
  21. Soltero-Rivera M, Battersby I, Morrison J, Spofford N, Weese JS. Antimicrobial use practices in canine and feline patients with co-morbidities undergoing dental procedures in primary care practices in the US. PLoS One. 2024 Jul 10;19(7):e0305533. doi: 10.1371/journal.pone.0305533. PMID: 38985775; PMCID: PMC11236167.
  22. Weese JS, Battersby I, Morrison J, Spofford N, Soltero-Rivera M (2023) Antimicrobial use practices in canine and feline dental procedures performed in primary care veterinary practices in the United States. PLoS ONE 18(12): e0295070. https://doi.org/10.1371/journal.pone.0295070
  23. Coxeter PD, Mar CD, Hoffmann TC. Parents’ Expectations and Experiences of Antibiotics for Acute Respiratory Infections in Primary Care. Ann Fam Med. 2017;15(2):149-154. doi:10.1370/afm.2040
  24. Radice M, Martino PA, Reiter AM. Evaluation of Subgingival Bacteria in the Dog and Susceptibility to Commonly Used Antibiotics. Journal of Veterinary Dentistry. 2006;23(4):219-224. doi:10.1177/089875640602300404
  25. König E, Ziegler HP, Tribus J, Grisold AJ, Feierl G, Leitner E. Surveillance of Antimicrobial Susceptibility of Anaerobe Clinical Isolates in Southeast Austria: Bacteroides fragilis Group Is on the Fast Track to Resistance. Antibiotics. 2021; 10(5):479. https://doi.org/10.3390/antibiotics10050479
  26. Kim T, Choi Y-D, Hur W, Lee S-W, La T-M. Antimicrobial susceptibility of Porphyromonas spp isolated from dogs with periodontal disease in South Korea. Front Vet Sci. 2025;12:1684907. doi:10.3389/fvets.2025.1684907
  27. Tsang W, Linde A, Krumbeck JA, Wu G, Kim YJ, Lushington GH, Melgarejo T. Occurrence of Antimicrobial Resistance Genes in the Oral Cavity of Cats with Chronic Gingivostomatitis. Animals. 2021; 11(12):3589. https://doi.org/10.3390/ani11123589
  28. Soltero-Rivera M, Goldschmidt S, Arzi B. Feline chronic gingivostomatitis: current concepts in clinical management. Journal of Feline Medicine and Surgery. 2023;25(8). doi:10.1177/1098612X231186834
  29. Anderson JG, Hennet P. Management of Severe Oral Inflammatory Conditions in Dogs and Cats. Vet Clin North Am Small Anim Pract. 2022;52(1):159-184. doi:10.1016/j.cvsm.2021.09.008
  30. Song B. Hyaluronic Acid: A Review of Clinical Applications in Human and Veterinary Dentistry. J Vet Dent. Published online September 23, 2025. doi:10.1177/08987564251379636
  31. Pilloni A, Shirakata Y, Marini L, Božić D, Miron RJ, Rotundo R, Stavropoulos A, Sculean A. Hyaluronic acid: A novel approach in regenerative/reconstructive periodontal therapy? Periodontol 2000. 2025;00:1-28. doi: 10.1111/prd.12644. 
  32. Rossi A, Anderson JG. A case series and review of canine idiopathic osteonecrosis of the jaw. Front Vet Sci. 2025;12:1614645. doi:10.3389/fvets.2025.1614645
  33. Seo MH, Eo MY, Myoung H, Kim SM, Lee JH. The effects of pentoxifylline and tocopherol in jaw osteomyelitis. J Korean Assoc Oral Maxillofac Surg. 2020;46(1):19-27. doi:10.5125/jkaoms.2020.46.1.19
  34. Jelin-Uhlig S, Weigel M, Ott B, Imirzalioglu C, Howaldt H-P, Böttger S, Hain T. Bisphosphonate-Related Osteonecrosis of the Jaw and Oral Microbiome: Clinical Risk Factors, Pathophysiology and Treatment Options. International Journal of Molecular Sciences. 2024; 25(15):8053. https://doi.org/10.3390/ijms25158053